Driven to Deliver Innovative Treatments
Nabriva Therapeutics (nabriva.com) scores 53 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 2nd percentile of 17179 Healthcare brands.
Nabriva Therapeutics is a commercial-stage biopharmaceutical company headquartered in Vienna, Austria, founded in 2005. The company develops innovative anti-infective agents aimed at treating serious infectious diseases. It positions itself as a dedicated leader in infectious disease treatment, pursuing collaborations and licensing opportunities to expand its pipeline. Its target audience includes healthcare providers, patients with serious infections, and potential pharmaceutical partners.
| Brand Name | Nabriva Therapeutics |
|---|---|
| Domain | nabriva.com |
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Vienna |
| Main Competitors | Paratek Pharmaceuticals (75/100), Melinta Therapeutics (74/100), Spero Therapeutics (75/100), Entasis Therapeutics (65/100), Basilea Pharmaceutica, Tetraphase Pharmaceuticals |
Moz Domain Authority 42/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #3,371,634 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections." (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), Facebook, Instagram; no detected presence on LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Nabriva Therapeutics?", Claude could identify the brand as of October 2026. Nabriva Therapeutics is a biopharmaceutical company focused on developing antibiotics to treat serious infections, particularly community-acquired bacterial pneumonia. It's known for developing lefamulin (marketed as Xenleta), a pleuromutilin antibiotic approved by the FDA in 201 Best known for Developing Xenleta (lefamulin), the first pleuromutilin antibiotic approved for use in humans in the US.
When asked "Best brands similar to Nabriva Therapeutics?", Claude would recommend Nabriva Therapeutics as of October 2026. I'd mention it in the context of antibiotic development companies or novel antibiotic classes, since Nabriva's lefamulin was a notable new mechanism approved amid concerns over antibiotic resistance.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Nabriva Therapeutics's main competitors in Healthcare: Paratek Pharmaceuticals (75/100), Melinta Therapeutics (74/100), Spero Therapeutics (75/100), Entasis Therapeutics (65/100).
Sources: Brand Analyzer scan
Nabriva Therapeutics has limited AI-search visibility, scoring 27/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 29, recommendation 35). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Nabriva Therapeutics official site
Nabriva Therapeutics was founded in 2005. Nabriva Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Nabriva Therapeutics is headquartered in Vienna. Nabriva Therapeutics operates in the Healthcare category.
Sources: Wikidata
Nabriva Therapeutics scores 35/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Nabriva Therapeutics official site
Nabriva Therapeutics is a commercial-stage biopharmaceutical company based in Vienna, Austria, founded in 2005. It focuses on developing innovative anti-infective agents to treat serious infectious diseases.
Sources: Nabriva Therapeutics official site
Nabriva Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Nabriva Therapeutics official site
Nabriva Therapeutics develops and commercializes anti-infective agents designed to treat serious infections. The company also pursues collaborations and licensing agreements to expand its pipeline of infectious disease treatments.
Sources: Nabriva Therapeutics official site
Nabriva Therapeutics scores 27/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Nabriva Therapeutics has a weak AI-visibility profile at 27/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (35/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #3,371,634 (Tranco) and a Moz Domain Authority of 42/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Nabriva Therapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Nabriva Therapeutics: METTLER TOLEDO (53/100), Magic Mobility Rentals (53/100), Verily Me | Lightpath (53/100), Peptides EU (53/100).
A step up - brands to learn from: Word of Mouth Technology (56/100), Werskincare (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.